Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Stoke Therapeutics, Inc. (STOK)

Stoke Therapeutics files prospectus for up to $200 million in at-the-market share sales

Neutral Impact 3 of 5 financing Written later

Stoke Therapeutics filed a prospectus supplement on August 3, 2026, covering the offer and sale of up to $200 million of common stock through Cantor Fitzgerald under an existing May 2022 sales agreement. The filing makes new share issuance possible, which could dilute existing shareholders, but the filing itself does not state how many shares have been sold or at what prices.

Key points

  • Prospectus supplement filed August 3, 2026 covers up to $200,000,000 of Placement Shares.
  • Sales run through Cantor Fitzgerald & Co. under the Controlled Equity Offering sales agreement dated May 20, 2022.
  • Offering is made under an automatic shelf registration statement (Form S-3ASR, File No. 333-294402) filed March 18, 2026.
  • Fenwick & West LLP legal opinion is filed as Exhibit 5.1.

The filing

CompanyStoke Therapeutics, Inc. (STOK)
Form8-K, current report
Filed with the SECAug 3, 2026, 5:06 PM ET
Accession number0001193125-26-330804

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 03, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.